Artificial Pancreas Guidance Allows For More Flexibility In Trial Design
This article was originally published in The Gray Sheet
Executive Summary
FDA’s final guidance on the design and clinical study of artificial pancreas systems broadens the study endpoints permissible for the devices, which aim to “close the loop” in the treatment of type 1 diabetes.